NASDAQ:AKTX Akari Therapeutics (AKTX) Stock Price, News & Analysis → Central Banks Preparing for US Dollar Collapse? (From Behind the Markets) (Ad) Free AKTX Stock Alerts $1.85 -0.01 (-0.54%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$1.72▼$1.9050-Day Range$1.80▼$2.7052-Week Range$1.66▼$5.50Volume13,382 shsAverage Volume13,858 shsMarket Capitalization$10.45 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get Akari Therapeutics alerts: Email Address Ad Behind the MarketsCentral Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.Find out how you can protect yourself now >>> About Akari Therapeutics Stock (NASDAQ:AKTX)Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.Read More AKTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AKTX Stock News HeadlinesMarch 29, 2024 | americanbankingnews.comShort Interest in Akari Therapeutics, Plc (NASDAQ:AKTX) Drops By 37.5%March 23, 2024 | americanbankingnews.comAkari Therapeutics (NASDAQ:AKTX) Earns Sell Rating from Analysts at StockNews.comMarch 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.March 17, 2024 | msn.comPVL: Fifi Sharma, Ced Domingo power Akari romp of NxledMarch 7, 2024 | bizjournals.comPetri Dish: C4’s deal with Merck KGaA; Boston and California biotechs mergeMarch 6, 2024 | stockhouse.comSHAREHOLDER UPDATE: Halper Sadeh LLC Investigates AKTX, HES, TGAN, NSMarch 5, 2024 | businesswire.comAKTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Akari Therapeutics, Plc Is Fair to ShareholdersFebruary 27, 2024 | msn.comPVL: Grethcel Soltones, Akari still a work in progressMarch 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.February 25, 2024 | msn.comPVL: Ced Domingo has a quiet Akari debut as she adjusts to new systemFebruary 24, 2024 | msn.comPVL: Cignal turns back Akari to open All-Filipino bidFebruary 16, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Set to End Week Higher in Friday TradingFebruary 9, 2024 | msn.comPVL: Akari’s Max Juangco taking pressure of her pro debut in strideFebruary 7, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Slightly Lower in Wednesday TradingFebruary 2, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Trend Lower in Friday Trading But End Week HigherJanuary 23, 2024 | investing.comAkari Therapeutics PLC (AKTX)January 22, 2024 | msn.comPVL: Faith Nisperos, Akari Chargers aim for Final FourJanuary 2, 2024 | finanznachrichten.deAkari Therapeutics Plc: Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement FinancingJanuary 2, 2024 | finance.yahoo.comAkari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement FinancingJanuary 2, 2024 | finance.yahoo.comAkari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement FinancingDecember 16, 2023 | msn.comAkari Therapeutics Plc - ADR (AKTX) Price Target Increased by 45.45% to 81.60December 14, 2023 | finance.yahoo.comAkari Therapeutics to Present at Biotech Showcase 2024December 2, 2023 | investing.comAkari Therapeutics (AKTX) Earnings Dates & ReportsDecember 1, 2023 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Poised to End Week Flat in Friday TradingNovember 28, 2023 | sg.finance.yahoo.comAkari Therapeutics, Plc (CLA.F)November 24, 2023 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Climb Higher FridayNovember 16, 2023 | finance.yahoo.comAkari Therapeutics Presents Poster on Progress in Pre-Clinical Development of Long-Acting PAS-Nomacopan as a Potential Treatment for Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development ConferenceSee More Headlines Receive AKTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Akari Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/31/2020Today3/28/2024Next Earnings (Estimated)5/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:AKTX CUSIPN/A CIK1541157 Webwww.akaritx.com Phone442080040261Fax646-843-9352Employees15Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio1.56 Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.48 per share Price / Book3.85Miscellaneous Outstanding Shares5,650,000Free Float2,159,000Market Cap$10.45 million OptionableNot Optionable Beta1.02 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMs. Rachelle Suzanne Jacques (Age 53)President, CEO & Director Comp: $1.38MMs. Wendy F. DiCicco CPA (Age 57)Interim Chief Financial Officer Ms. Melissa Bradford-Klug (Age 54)Chief Operating Officer Dr. Miles Nunn (Age 55)Chief Scientific Officer Dr. John F. Neylan III (Age 71)M.D., Executive VP & Chief Medical Officer Ms. Beth-Anne LangSenior Vice President of Regulatory AffairsAnnie MackFinancial ControllerMore ExecutivesKey CompetitorsMonopar TherapeuticsNASDAQ:MNPRCadrenal TherapeuticsNASDAQ:CVKDASLAN PharmaceuticalsNASDAQ:ASLNNightHawk BiosciencesNYSE:NHWKImunonNASDAQ:IMNNView All CompetitorsInstitutional OwnershipOmnia Family Wealth LLCBought 28,511 shares on 2/5/2024Ownership: 1.551%View All Institutional Transactions AKTX Stock Analysis - Frequently Asked Questions How have AKTX shares performed in 2024? Akari Therapeutics' stock was trading at $3.12 at the start of the year. Since then, AKTX shares have decreased by 40.7% and is now trading at $1.85. View the best growth stocks for 2024 here. Are investors shorting Akari Therapeutics? Akari Therapeutics saw a decline in short interest during the month of March. As of March 15th, there was short interest totaling 6,000 shares, a decline of 37.5% from the February 29th total of 9,600 shares. Based on an average trading volume of 9,600 shares, the short-interest ratio is presently 0.6 days. Approximately 0.1% of the shares of the stock are short sold. View Akari Therapeutics' Short Interest. When is Akari Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 6th 2024. View our AKTX earnings forecast. How were Akari Therapeutics' earnings last quarter? Akari Therapeutics, Plc (NASDAQ:AKTX) released its earnings results on Tuesday, March, 31st. The biopharmaceutical company reported ($7.80) earnings per share for the quarter, missing analysts' consensus estimates of ($2.80) by $5.00. When did Akari Therapeutics' stock split? Akari Therapeutics's stock reverse split on the morning of Thursday, August 17th 2023. The 1-20 reverse split was announced on Thursday, August 17th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, August 17th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Akari Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Akari Therapeutics investors own include SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Biocept (BIOC), OPKO Health (OPK), Anavex Life Sciences (AVXL), Rigel Pharmaceuticals (RIGL), Teva Pharmaceutical Industries (TEVA), Vascular Biogenics (VBLT) and Heat Biologics (HTBX). Who are Akari Therapeutics' major shareholders? Akari Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Omnia Family Wealth LLC (1.55%). View institutional ownership trends. How do I buy shares of Akari Therapeutics? Shares of AKTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AKTX) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 Media“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyOnly a fool would buy Nvidia today… Porter & CompanyMost important medical advance in 100 yearsThe Oxford ClubFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akari Therapeutics, Plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.